News Hub | News Direct

Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
Article thumbnail News Release

Destiny Pharma upbeat on prospects for C. Difficile treatment

Destiny Pharma PLC

Destiny Pharma PLC (AIM:DEST, OTC:DTTYF) chief scientific officer Bill Love speaks to Proactive after results from a study into its C. Difficile treatment platform NTCD-M3 were published in the Microbiology Spectrum journal. Love explains what makes the platform so promising from Destiny's point of view, before going on to reveal more about the plans for bringing NTCD-M3 to the market. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

April 06, 2023 09:53 AM Eastern Daylight Time

Video
Article thumbnail News Release

Aqua Cultured Foods Closes $5.5M Seed Round led by Stray Dog Capital

AquaCultured Foods

Food tech startup Aqua Cultured Foods today announced it has raised $5.5 million in seed funding to bring its ultra-realistic seafood alternatives to market. The round was led by Stray Dog Capital, a venture capital fund specializing in alternative protein investments, with participation from H Venture Partners, Aztec Capital Management and Amplifica Capital, along with follow-on investment from current investors Supply Change Capital, Big Idea Ventures, HPA, Aera VC, Kingfisher Family Investments, and Swiss Pampa. The round also included a strategic investment from CJ CheilJedang, a South Korea-based global food and bio company owning renowned brands such as Bibigo. Aqua will use the investment to equip its new facility, scale up production, bring products to market, add key talent, and expand its roster of restaurant and foodservice outlets for product introductions this year. “We appreciate having mission-aligned partners that offer strong strategic value for the next phase of our growth, which will involve building up the business and brand,” said Anne Palermo, CEO of Aqua. “Being good stewards of investor capital is important to us, so along with hitting milestones earlier than expected, we are benefiting from government programs, academic resources, and other advantages to get to market quickly.” Aqua’s primary value is its low cost of scaling and its path to price parity, thanks to proprietary fermentation methods that use relatively affordable inputs and equipment. The company recently acquired a food-grade facility that was already built out nearly to its requirements—which it estimates will save more than a million dollars in construction costs. Aqua was recently accepted into the Illinois Office of Business Development’s EDGE program that provides tax incentives to growing companies, which will save hundreds of thousands of dollars in taxes over the next 10 years. “The adage is true that early-stage funds heavily weight investment conviction in people, and less in technologies or products given the embryonic nature of companies at these stages, but Aqua already boasts strength across its team, product, and key partnerships already in place,” said Johnny Ream, Partner at Stray Dog Capital. “We are interested in backing founding teams leveraging unique technologies and approaches that drive a more sustainable future; the work Aqua is doing with alt-seafood has immense potential to drive both human and planetary benefits in a massive $100B+ global market.” The global plant-based seafood market was valued at $42.1 million in 2021, and is projected to reach $1.3 billion by 2031 with a CAGR of more than 42 percent as wild fish stocks are further depleted. In addition to depleted fish populations, commercial fishing practices result in damage to ecosystems, plastic waste, and “bycatch” of non-target species. As fish farming increases, so does habitat destruction, pollution and diseases spread to wild fish, and the industry’s reliance on antibiotics and wild-caught fish for feed. Despite its health halo, fish contains microplastics, mercury, pesticides, antibiotics, dioxin and PCBs. High in cholesterol and saturated fats, seafood, in particular finfish, is a good source of foodborne illness caused by bacteria, viruses and parasites. Aqua is developing calamari, shrimp, scallops, and filets of tuna and whitefish with proprietary mycoprotein fermentation processes that do not use any animal inputs, genetic altering or modification. Unlike plant-based processed foods formulated with starches and protein isolates, Aqua’s alt-seafood retains its naturally occurring fiber, protein, and other micronutrients. The company also produces minced “seafood” fillings for applications such as dumplings, ravioli, and sushi rolls. For images visit https://app.box.com/s/wfbrvgraf2ty2b7by5h6ahjsaqrd8zx3. Follow Aqua Cultured Foods LinkedIn https://www.linkedin.com/company/aquacultured-foods Instagram https://www.instagram.com/aquaculturedfoods Facebook https://www.facebook.com/AquaCulturedFoods Twitter https://twitter.com/eatAquaFoods ‎ About Aqua Cultured Foods Aqua Cultured Foods is an innovative food technology startup developing the world’s first whole-muscle cut seafood alternatives created through microbial fermentation. Its novel technology produces a sustainable, complete protein source using only a fraction of the resources required by traditional aquaculture. As an R&D company with a focus on product commercialization, Aqua Cultured Foods occupies a unique position in the burgeoning alt-seafood market as well as within the fermentation industry. The company’s mission is to mitigate global challenges such as overfishing, climate change and feeding the world’s expanding population with delicious, nutrient-rich foods. For more information visit https://www.aquaculturedfoods.com. About Stray Dog Capital Stray Dog Capital is a venture capital fund investing in innovative, early-stage companies across the food, beverage, and biotechnology sectors that are driving a healthier, humane, and more sustainable future. Stray Dog Capital supports its portfolio of investments with broad experience from its team as entrepreneurs, operators, advisors, and investors. www.straydogcapital.com. ### Contact Details Gary Smith +1 818-783-0569 gary@evolotuspr.com Company Website https://www.aquaculturedfoods.com

April 06, 2023 09:05 AM Eastern Daylight Time

Image
Article thumbnail News Release

Futura Medical "confident of getting FDA approval this quarter"

Futura Medical PLC

Futura Medical PLC (AIM:FUM, OTC:FAMDF) CEO James Barder speaks to Proactive following the release of full year results for 2022. Barder says that despite losses, revenues "are now rapidly coming over the horizon" and he suggests "the last two years have been very very good for us". He adds that he's "confident of getting FDA approval for MED3000 this quarter" Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

April 06, 2023 06:12 AM Eastern Daylight Time

Video
Article thumbnail News Release

Faron Pharmaceuticals moving "into next phase" with new CFO

Faron Pharmaceuticals Oy

Faron Pharmaceuticals Limited (AIM:FARN, OTC:FPHAF) chief financial officer James O'Brien speaks to Proactive on his second day in the new role. O'Brien reveals more about what he believes he can bring to Faron, highlighting his experience in the US capital markets. He adds that Faron is now moving "into [its} next phase of growth." Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

April 06, 2023 05:27 AM Eastern Daylight Time

Video
Article thumbnail News Release

MGC Pharmaceuticals' focus "will not change" despite psilocybin news

MGC Pharmaceuticals Ltd

MGC Pharmaceuticals Ltd (LSE:MXC, OTC:MGCLF, ASX:MXC) chief commercial officer Robert Clements speaks to Proactive after announcing that the company has been granted permission by the Slovenian government to conduct research into psilocybin, a naturally occurring psychedelic compound found in certain types of mushrooms. The company will work in partnership with other pharmaceutical companies to determine the best potential use for psilocybin. Clements says that "the focus of MGC will not change" despite the news, adding that it is fully committed to its current pipeline of products. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

April 06, 2023 05:14 AM Eastern Daylight Time

Video
Article thumbnail News Release

Xeris Biopharma enters research collaboration with Regeneron Pharmaceuticals to advance XeriJect

Xeris Biopharma Holdings

Xeris Biopharma chairman and CEO Paul Edick joins Proactive's Natalie Stoberman to share details behind its research evaluation collaboration with Regeneron Pharmaceuticals for further XeriJect development. Edick says the agreement will see Xeris using its proprietary drug-formulation platform, XeriJect, to develop ultra-highly concentrated, ready-to-use, small volume subcutaneous injections of two undisclosed monoclonal antibodies developed by Regeneron. Xeris will receive an upfront payment and potential milestone payments for preclinical achievements. Regeneron will have an option to commercially license the Xeris technology for such molecules and nominate additional molecules for reformulation and potential commercialization. Contact Details Proactive Investors +1 347-449-0879 na-editorial@proactiveinvestors.com

April 05, 2023 01:18 PM Eastern Daylight Time

Video
Article thumbnail News Release

HealthLynked discusses year-end financials and MedOfficeDirect prospects in development

HealthLynked

HealthLynked chairman and CEO Dr Michael Dent and chief financial officer George O'Leary join Proactive's Natalie Stoberman to share highlights from the company's fourth-quarter and full-year 2022 financial results. HealthLynked reported revenue of $5.86 million, a 10% decrease compared to $6.50 million in 2021. Dent says the decline is primarily attributed to decreases in patient service revenue at the Naples Women’s Center and Bridging the Gap facilities, as well as lower product revenue from MedOfficeDirect. However, the company has reported that the decrease was partially offset by revenue increases at its Naples Center for Functional Medicine facility and revenue from the newly-acquired Aesthetics Enhancements Unlimited practice. Contact Details Proactive Investors +1 347-449-0879 na-editorial@proactiveinvestors.com

April 05, 2023 01:13 PM Eastern Daylight Time

Video
Article thumbnail News Release

Algernon NeuroScience reports successful second cohort dosing in DMT clinical study

Algernon Pharmaceuticals Inc.

Algernon Pharmaceuticals CEO Christopher Moreau joined Steve Darling from Proactive to share news the company’s subsidiary Algernon Neuroscience has completed dosing of the second cohort in the Phase 1 clinical study of DMT. Moreau tells Proactive the study is to identify the safety and tolerability of DMT when administered as an intravenous bolus followed by a prolonged infusion of 6 hours which has never been studied clinically. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

April 05, 2023 01:03 PM Eastern Daylight Time

Video
Article thumbnail News Release

BioHarvest Sciences announces launch of “Real Stories” media campaign for VINIA red grape supplement

BioHarvest Sciences Inc.

BioHarvest Sciences CEO Ilan Sobel joined Steve Darling from Proactive to share news the company will be launching a major media campaign to support its flagship supplement VINIA in the United States. Sobel tells Proactive the campaign will use real VINIA users telling their ‘Real Stories” on television and social media. The science behind the product will also be highlighted. BioHarvest has set its 2023 guidance with plans to increase global VINIA sales to over US$17 million. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

April 05, 2023 12:25 PM Eastern Daylight Time

Video
1 ... 137138139140141 ... 301